Clinical Trials Using Carbon-11 Acetate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Carbon-11 Acetate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Carbon-11 Acetate PET / CT in Diagnosing Participants with Glioma

    This research trial studies how well carbon-11 acetate positron emission tomography (PET) / computed tomography (CT) works in diagnosing participants with glioma. Carbon-11 acetate is an experimental radioactive material which moves through your body after it has been injected into one of your veins. The PET / CT scan may be able to trace the small amount of carbon-11 acetate and reveal areas in your brain that are burning carbon-11 acetate for fuel.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Carbon-11 Acetate PET / CT Imaging in Evaluating Response to Radium Ra 223 Dichloride Therapy in Patients with Hormone-Resistant Metastatic Prostate Cancer

    This pilot clinical trial studies carbon-11 acetate positron emission tomography / computed tomography (PET / CT) in evaluating response to radium Ra 223 dichloride therapy in patients with prostate cancer that has not responded to previous treatment with hormones and that has spread to the bones. Carbon-11 acetate is a specialized radioactive drug that is used to allow imaging of tissue using a PET / CT scanner which is specialized to detect a small radioactive signal. Carbon-11 acetate is used to evaluate cell growth and how fast cells replicate. The amount of carbon-11 acetate that is taken up by cancer cells before and after radium Ra 223 therapy may help to understand whether patients with hormone-resistant metastatic prostate cancer are responding to treatment.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • 18F-FSPG PET in Imaging Patients with Liver Cancer before Undergoing Surgery or Transplant

    This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Multi-tracer PET in Imaging Patients with Brain Tumors

    This pilot clinical trial studies multi-tracer positron emission tomography (PET) in imaging patients with brain tumors. PET uses radioactive labels (tracer), such as fludeoxyglucose F 18 (18F-FDG), fluorine F 18 fluorothymidine (18F-FLT), carbon 11 acetate (11C-ACE), or oxygen 15 water (15O-H2O), which can recognize differences between tumor and healthy brain. Multi-tracer PET may help find tumor proliferation (movement), glucose metabolism (sugars), blood flow, and growth rate in order to better predict treatment response.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah